Zenith Epigenetics
11
4
5
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
27.3%
3 terminated/withdrawn out of 11 trials
40.0%
-46.5% vs industry average
0%
0 trials in Phase 3/4
100%
2 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
Role: collaborator
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
Role: lead
The COSMYC Trial (COmbined Suppression of MYC)
Role: collaborator
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Role: collaborator
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Role: collaborator
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Role: lead
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Role: lead
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
Role: collaborator
A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Role: lead
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Role: lead
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
Role: lead
All 11 trials loaded